Mononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma
- PMID: 38333608
- PMCID: PMC10850347
- DOI: 10.3389/fneur.2024.1338899
Mononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma
Abstract
Introduction: Mononeuritis multiplex is frequently related to vasculitic neuropathy and has been reported only sporadically as an adverse event of immune checkpoint inhibitors.
Methods: Case series of three patients with mononeuritis multiplex-all with mesothelioma-identified in the databases of two French clinical networks (French Reference Center for Paraneoplastic Neurological Syndromes, Lyon; OncoNeuroTox, Paris; January 2015-October 2022) set up to collect and investigate n-irAEs on a nationwide level.
Results: Three patients (male; median age 86 years; range 72-88 years) had pleural mesothelioma and received 10, 4, and 6 cycles, respectively, of first-line nivolumab plus ipilimumab combined therapy. In patient 1, the neurological symptoms involved the median nerves, and in the other two patients, there was a more diffuse distribution; the symptoms were severe (common terminology criteria for adverse events, CTCAE grade 3) in all patients. Nerve conduction studies indicated mononeuritis multiplex in all patients. Peripheral nerve biopsy demonstrated necrotizing vasculitis in patients 1 and 3 and marked IgA deposition without inflammatory lesions in patient 2. Immune checkpoint inhibitors were permanently withdrawn, and corticosteroids were administered to all patients, leading to complete symptom regression (CTCAE grade 0, patient 2) or partial improvement (CTCAE grade 2, patients 1 and 3). During steroid tapering, patient 1 experienced symptom recurrence and spreading to other nerve territories (CTCAE grade 3); he improved 3 months after rituximab and cyclophosphamide administration.
Discussion: We report the occurrence of mononeuritis multiplex, a very rare adverse event of immune checkpoint inhibitors, in the three patients with mesothelioma. Clinicians must be aware of this severe, yet treatable adverse event.
Keywords: immune checkpoint inhibitor; mononeuritis multiplex; n-irAEs; nerve vasculitis; neurological immune-related adverse events; neurological toxicity; vasculitic neuropathy.
Copyright © 2024 Farina, Escalere, Dion, Moussy, Pegat, Villagrán-García, Devic, Lamiral, Seyve, Aure, Wang, Gorza, Streichenberger, Maisonobe, Honnorat, Birzu, Psimaras, Weisenburger-Lile and Joubert.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Mononeuritis multiplex as a rare and severe neurological complication of immune checkpoint inhibitors: a case report.J Med Case Rep. 2022 Feb 24;16(1):81. doi: 10.1186/s13256-022-03290-1. J Med Case Rep. 2022. PMID: 35197122 Free PMC article.
-
Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity.Brain Commun. 2023 May 27;5(3):fcad169. doi: 10.1093/braincomms/fcad169. eCollection 2023. Brain Commun. 2023. PMID: 37389303 Free PMC article.
-
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.Lancet Respir Med. 2019 Mar;7(3):260-270. doi: 10.1016/S2213-2600(18)30420-X. Epub 2019 Jan 16. Lancet Respir Med. 2019. PMID: 30660511 Clinical Trial.
-
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.Oncologist. 2019 Apr;24(4):435-443. doi: 10.1634/theoncologist.2018-0359. Epub 2018 Nov 27. Oncologist. 2019. PMID: 30482825 Free PMC article. Review.
-
Paediatric mononeuritis multiplex: a report of three cases and review of the literature.Neuromuscul Disord. 2003 Nov;13(9):751-6. doi: 10.1016/s0960-8966(03)00099-3. Neuromuscul Disord. 2003. PMID: 14561499 Review.
Cited by
-
Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors.Front Immunol. 2025 Feb 10;16:1496427. doi: 10.3389/fimmu.2025.1496427. eCollection 2025. Front Immunol. 2025. PMID: 39995675 Free PMC article.
-
Deterioration in multifocal motor neuropathy upon treatment of immune-related adverse events of checkpoint inhibition.Immunotherapy. 2024;16(9):597-601. doi: 10.1080/1750743X.2024.2342238. Epub 2024 May 16. Immunotherapy. 2024. PMID: 39052281 Free PMC article.
References
-
- Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. (2021) 397:375–86. doi: 10.1016/S0140-6736(20)32714-8 - DOI - PubMed
-
- Collins MP, Dyck PJB, Gronseth GS, Guillevin L, Hadden RD, Heuss D, et al. . Peripheral nerve society guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. (2010) 15:176–84. doi: 10.1111/j.1529-8027.2010.00281.x, PMID: - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous